DEDICATED TO PROVIDING SUPPORT FOR YOU AND YOUR PATIENTS

CYCLOSET®
Savings Program

The CYCLOSET® Co-Pay Savings Program is designed to help your eligible patients save on their prescriptions.

CYCLOSET Co-pay Card CYCLOSET Co-pay Card

AS LITTLE AS

dollar-symbol

CO-PAY FOR COMMERCIALLY ELIGIBLE PATIENTS*

*This offer is only valid for patients with commercial insurance. Uninsured patients are not eligible. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. This offer is not valid in Massachusetts or Minnesota or where otherwise prohibited, taxed or otherwise restricted. Click here for full Eligibility Terms and Conditions.

Patient is responsible for all additional costs and expenses after application of the maximum benefits. For information about the maximum benefits, please call 1-866-686-0049.

Download co-pay cards today

Co-pay assistance is available for commercially eligible patients in your practice. Click below to download co-pay cards. If you are new to our savings program, a brief enrollment questionnaire is all that’s required.

download-button

Discover our Patient Assistance Program

Bausch Health is committed to helping eligible patients in financial need—and without prescription insurance coverage—receive our prescription products at no cost. Click below to view options available through the Bausch Health Patient Assistance Program, along with Eligibility Terms and Conditions.

button
CYCLOSET tablets CYCLOSET tablets

Request CYCLOSET® samples

Get appropriate new patients started on CYCLOSET® tablets in just a few simple steps.

request-button

Resources for your practice

Learn more about CYCLOSET® and help optimize your patients’ experience.

PRESCRIBING GUIDE
CYCLOSET Prescribing Guide CYCLOSET Prescribing Guide

At-a-glance assistance for prescribing CYCLOSET®

PATIENT DOSING GUIDE
CYCLOSET Patient Dosing Guide CYCLOSET Patient Dosing Guide

Provides patients with information on dosing.

PATIENT BROCHURE
CYCLOSET Patient Brochure CYCLOSET Patient Brochure

Provides patients with information about type 2 diabetes and how CYCLOSET® may help.

SAFETY PROFILE FLASHCARD
CYCLOSET Safety Profile Flashcard CYCLOSET Safety Profile Flashcard

Provides results on nausea from the 52-week safety trial.

A TARGETED MECHANISM OF ACTION

button
See More

INDICATION

CYCLOSET® (bromocriptine mesylate) 0.8 mg tablets is a dopamine receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

LIMITATIONS OF USE

  • CYCLOSET should not be used to treat type 1 diabetes or diabetic ketoacidosis.
  • Limited efficacy data in combination with thiazolidinediones.
  • Efficacy has not been confirmed in combination with insulin.

IMPORTANT SAFETY INFORMATION

Contraindications

CYCLOSET is contraindicated in:

  • Patients with hypersensitivity to ergot-related drugs, bromocriptine or to any of the excipients in CYCLOSET.
  • Patients with syncopal migraines. May precipitate hypotension.
  • Postpartum patients. Serious and life-threatening adverse reactions have been reported.
  • Lactating patients. CYCLOSET contains bromocriptine which inhibits lactation.
See Less

IMPORTANT SAFETY INFORMATION

Contraindications

CYCLOSET is contraindicated in:

  • Patients with hypersensitivity to ergot-related drugs, bromocriptine or to any of the excipients in CYCLOSET.
  • Patients with syncopal migraines. May precipitate hypotension.
  • Postpartum patients. Serious and life-threatening adverse reactions have been reported.
  • Lactating patients. CYCLOSET contains bromocriptine which inhibits lactation.

INDICATION

CYCLOSET® (bromocriptine mesylate) 0.8 mg tablets is a dopamine receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

LIMITATIONS OF USE

  • CYCLOSET should not be used to treat type 1 diabetes or diabetic ketoacidosis.
  • Limited efficacy data in combination with thiazolidinediones.
  • Efficacy has not been confirmed in combination with insulin.

Orthostatic Hypotension/Syncope

  • CYCLOSET can cause orthostatic hypotension and syncope, particularly upon initiation or dose escalation. Use caution in patients taking antihypertensive medications. Orthostatic vital signs should be assessed prior to initiation of CYCLOSET and periodically thereafter.
  • Advise patients during early treatment to avoid situations that could lead to injury if syncope were to occur, and to make slow postural changes.

Psychotic Disorders

  • The use of CYCLOSET in patients with severe psychotic disorders is not recommended.

Impulse Control/Compulsive Behaviors

  • Consider dose reduction or discontinuation of CYCLOSET if a patient develops intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably and/or other intense urges.

Somnolence

  • CYCLOSET may cause somnolence, particularly when initiating therapy. Advise patients not to drive or operate heavy machinery if symptoms of somnolence occur.

Concomitant Use of Dopamine Antagonists or Agonists

  • Concomitant use with dopamine antagonists, such as neuroleptic agents, may diminish the effectiveness of both drugs and is not recommended.
  • Effectiveness and safety are unknown in patients already taking dopamine receptor agonists for other indications and concomitant use is not recommended.

Risks in Postpartum Patients

  • CYCLOSET is contraindicated in postpartum patients. Serious and life-threatening adverse reactions have been reported in postpartum women who were administered bromocriptine for inhibition of lactation. These risks may be higher in postpartum patients with cardiovascular disease. The indication for use of bromocriptine for inhibition of postpartum lactation was withdrawn from bromocriptine-containing products and is not approved for CYCLOSET.

Safety and Effectiveness in Pediatrics

  • The safety and effectiveness of CYCLOSET in pediatric patients have not been established.

Adverse Reactions

  • In clinical trials, the most common adverse reactions reported in ≥5% of patients treated with CYCLOSET, and reported more commonly than in patients treated with placebo, included nausea, fatigue, dizziness, vomiting, and headache. Postmarketing reports with higher doses of bromocriptine used for other indications include psychotic disorders, hallucinations, and fibrotic complications.

Drug Interactions

  • May increase the unbound fraction of highly protein-bound therapies, altering their effectiveness and safety profiles.
  • May increase ergot-related side effects or reduce ergot effectiveness for migraines if co-administered within 6 hours of ergot-related drugs.
  • Extensively metabolized by CYP3A4. Limit CYCLOSET dose to 1.6 mg/day during concomitant use of moderate CYP3A4 inhibitors. Avoid concomitant use of CYCLOSET with strong CYP3A4 inhibitors.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.